Effects of Tirzepatide on Weight Loss and Chronic Inflammation in People With HIV

You may be eligible if

• Age ≥ 18 years
• HIV-1 infection (well controlled)
• Documented HIV-1 infection ≥ 1 year prior to study entry (ELISA confirmed by Western blot or HIV-1 RNA) AND
• HIV-1 RNA \<200 copies/mL for ≥ 6 months
• Stable ART
• · Receiving a stable antiretroviral regimen for at least 1 year prior to study entry
• Overweight
• BMI ≥27 kg/m2 plus at least one weight-related condition (defined as a medical history of dyslipidemia, hypertension, cardiovascular disease, or obstructive sleep apnea) OR Obese
• BMI ≥ 30 kg/m2